Meningococcal C conjugate vaccine: The experience in England and Wales
Meningococcal C conjugate vaccine: The experience in England and Wales
复制标题
DOI：
10.1016/j.vaccine.2009.04.067
复制
发表时间：
2009-06-24
期刊：
影响因子：
5.5
通讯作者：
Miller, Elizabeth
中科院分区：
文献类型：
--
作者：
Campbell, Helen;Borrow, Ray;Miller, Elizabeth
联合王国于1999年11月引进了C型脑膜炎球菌结合疫苗，同时推出了一项全面的脑膜炎球菌监测战略，以支持和通报疫苗规划。这些监测数据提供了重要信息，说明该规划通过直接和间接保护所取得的长期效果，并说明引入疫苗后引起侵袭性脑膜炎球菌感染的流行血清型和血清亚型。MCC免疫规划在控制血清C群疾病方面非常成功，并将继续进行评估。本文的目的是回顾过去9年来英格兰和威尔士的经验。2009爱思唯尔有限公司版权所有。
Meningococcal C conjugate vaccine was introduced in the UK in November 1999 together with a comprehensive meningococcal surveillance strategy to support and inform the vaccine programme. These surveillance data have provided important information on the long-term effectiveness of the programme, through direct and indirect protection, and on the prevalent serotypes and serosubtypes causing invasive meningococcal infection subsequent to vaccine introduction. The MCC immunization programme has been extremely successful in controlling serogroup C disease and continues to be evaluated. The aim of this paper is to review the experiences in England and Wales over the past 9 years. (C) 2009 Elsevier Ltd. All rights reserved.